Osteonecrosis of the jaw (ONJ) is a rare adverse event related to the use of antiresorptive therapies in patients with osteoporosis. However, the benefits of treatment outweigh the risk of developing ONJ.
- The frequency of osteonecrosis of the jaw (ONJ) is one in 10,000 to 100,000 patients treated with antiresorptive therapy for osteoporosis.
- Risk factors for ONJ include the duration and dose of antiresorptive therapy, poor dental hygiene, corticosteroid use and invasive dental procedures.
- The benefit of preventing an osteoporotic fracture often far outweighs the small risk of ONJ.
- In the setting of osteoporosis, most cases of ONJ are mild and represent delayed mucosal repair for which no specific treatment is required.
Picture credit: © SPL/Lawrence Lawry.